On January 9, the imported 9-valent HPV vaccine produced by Merck & Co., Ltd. was approved by China's National Medical Products Administration (NMPA) for women aged 9-14 years to be administered as a two-dose vaccine.
Since August 2022, after the "age expansion" vaccination of imported 9-valent HPV in China, the vaccination population has expanded from the past 16-26 years old to 9-45 years old, and women aged 9-45 years have previously adopted a three-dose vaccination schedule.
Has there been any change in the dosage in response to the news of this approval?Will it be adjusted?
That night, Merck revealed to The Paper that the nine-valent HPV vaccine it developed was only for female vaccinators aged 9-14 years old, and it was approved for two new doses in the vaccination program, and there was no change in the dose of a single shot, and there was no adjustment to the ** of a single dose. This means that the cost of immunization for this segment of the population will be reduced.
Qiao Youlin, a professor at the School of Medicine and Public Health at Peking Union Medical College, pointed out that girls aged 9-14 are the primary vaccination group recommended by the World Health Organization, and their HPV vaccination is easy to trigger a better immune response, and women who have not had sex will get the best prevention effect of HPV vaccine.
Pu Xiaowen, a cervical doctor at Shanghai First Maternity and Infant Health Hospital, also said in an interview with The Paper that after the expansion of the nine-valent HPV vaccine, the willingness of the 26-45-year-old group to be vaccinated is very strong, but compared with the 26-45-year-old population, the proportion of people aged 9-15 who receive the HPV vaccine is particularly small in China." The HPV vaccine should be recommended for the adolescent group, because for this part of the population, the HPV vaccine will be more effective if they have not experienced sexual life, and the earlier the HPV vaccine, the better the immune effect. ”
The Paper, for more original information, please **"The Paper" app).